These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8931775)

  • 1. Adverse effects of aluminium-chelating compounds for clinical use.
    Domingo JL
    Adverse Drug React Toxicol Rev; 1996 Aug; 15(3):145-65. PubMed ID: 8931775
    [No Abstract]   [Full Text] [Related]  

  • 2. [Possible side-effects of antidotal therapy].
    Wirth W
    Arch Toxikol; 1968; 24(1):71-82. PubMed ID: 4974058
    [No Abstract]   [Full Text] [Related]  

  • 3. Aluminium chelation in chronic haemodialysis and aluminium adjuvanted vaccines.
    Poltera AA
    Vaccine; 1999 Nov; 18(7-8):577-8. PubMed ID: 10660429
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of a desferrioxamine "microdose" to chelate aluminum in hemodialysis patients.
    Jorge C; Gil C; Possante M; Catarino MC; Cruz A; Andrade R; Teixeira R; Santos N; Ferreira A
    Clin Nephrol; 1999 Nov; 52(5):335-6. PubMed ID: 10585000
    [No Abstract]   [Full Text] [Related]  

  • 5. Fatal Aeromonas hydrophila bacteremia in a hemodialysis patient treated with deferoxamine.
    Lin SH; Shieh SD; Lin YF; De Brauwer E; Van Landuyt HW; Gordts B; Boelaert JR
    Am J Kidney Dis; 1996 May; 27(5):733-5. PubMed ID: 8629637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of aluminum 3-hydroxypyridin-4-one complexes: implications for aluminum redistribution subsequent to chelation therapy.
    Allen DD; Orvig C; Yokel RA
    Toxicology; 1994 Sep; 92(1-3):193-202. PubMed ID: 7940560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A report of pediatric SUCCIMER overdose.
    Sigg T; Burda A; Leikin JB; Gossman W; Umanos J
    Vet Hum Toxicol; 1998 Apr; 40(2):90-1. PubMed ID: 9554061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Harmful effects of common drugs on the visual apparatus. The oligo-elements and chelating agents. B. Chelating agents].
    van Oye R
    Bull Soc Belge Ophtalmol; 1972; 160(1):255-7. PubMed ID: 4625832
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of chelating agents in the treatment of aluminum overload.
    Domingo JL
    J Toxicol Clin Toxicol; 1989; 27(6):355-67. PubMed ID: 2697761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aluminium overload influences cognitive function in patients on dialysis.
    Kambova L; Ionova D; Kirijakov Z
    Nephrol Dial Transplant; 1994; 9(9):1357. PubMed ID: 7816312
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of hydroxypyridones and desferrioxamine on the mobilization of aluminium from tissues of aluminium-loaded rats.
    Florence AL; Gauthier A; Ward RJ; Crichton RR
    Neurodegeneration; 1995 Dec; 4(4):449-55. PubMed ID: 8846239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aluminum chelation: chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine.
    Yokel RA
    J Toxicol Environ Health; 1994 Feb; 41(2):131-74. PubMed ID: 8301696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unusual toxicity of deferoxamine.
    Sánchez Rodríguez A; Martín Oterino JA; Fidalgo Fernández MA
    Ann Pharmacother; 1999 Apr; 33(4):505-6. PubMed ID: 10332547
    [No Abstract]   [Full Text] [Related]  

  • 14. Growth failure and bone lesions due to desferrioxamine in thalassaemic patients.
    Caruso-Nicoletti M; Di Bella D; Pizzarelli G; Leonardi C; Sciuto C; Coco M; Di Gregorio F
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():957-60. PubMed ID: 10091171
    [No Abstract]   [Full Text] [Related]  

  • 15. Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity.
    Yokel RA; Meurer KA; Hong CB; Dickey KM; Skinner TL; Fredenburg AM
    Drug Metab Dispos; 1997 Feb; 25(2):182-90. PubMed ID: 9029049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined chelation based on glycosyl-mono- and bis-hydroxypyridinones for aluminium mobilization: solution and biodistribution studies.
    Chaves S; Dron PI; Danalache FA; Sacoto D; Gano L; Santos MA
    J Inorg Biochem; 2009 Nov; 103(11):1521-9. PubMed ID: 19748126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute toxicity studies of aluminium compounds: antidotal efficacy of several chelating agents.
    Llobet JM; Domingo JL; Gómez M; Tomás JM; Corbella J
    Pharmacol Toxicol; 1987 Apr; 60(4):280-3. PubMed ID: 3588526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidotes: benefits and risks.
    Proudfoot AT
    Toxicol Lett; 1995 Dec; 82-83():779-83. PubMed ID: 8597142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aluminum speciation studies in biological fluids. Part 5. A quantitative investigation of A1(III) complex equilibria with desferrioxamine, 2,3-dihydroxybenzoic acid, Tiron, CP20 (L1), and CP94 under physiological conditions, and computer-aided assessment of the aluminum-mobilizing capacities of these ligands in vivo.
    Desroches S; Biron F; Berthon G
    J Inorg Biochem; 1999 May; 75(1):27-35. PubMed ID: 10402674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid conversion from aluminium bone disease to hyperparathyroid bone disease by desferrioxamine.
    Terao N; Suzuki M; Homma S; Asano Y; Hosoda S; Furuse M
    Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1129-33. PubMed ID: 3216555
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.